Mylan to develop multiple sclerosis drug with Mapi Pharma

Consumer Healthcare News

Mylan will be working with the Israeli biopharmaceutical company Mapi Pharma on the development of a new multiple sclerosis drug.

The companies have agreed to partner on the development and commercialisation of GA Depot, a long-acting glatiramer acetate product, with Mylan acquiring global marketing rights to the drug.

“Mylan has acquired global marketing rights to GA Depot, a long-acting glatiramer acetate product for the treatment of multiple sclerosis.“

GA Depot is a proposed once-monthly injection for the treatment of patients with relapsing-remitting multiple sclerosis (MS), a form of MS that accounts for approximately 85 percent of initial diagnoses.

Mapi Pharma has already completed an open-label phase II clinical trial of this promising therapy, and is currently preparing to commence a pivotal phase III clinical trial to support marketing applications for the drug.

This agreement will see Mylan make an investment in Mapi Pharma, in addition to working alongside it to continue the development of GA Depot.

Rajiv Malik, president of Mylan, said: "We believe that our teams are well poised for a successful collaboration as we work through the remaining clinical and regulatory phases to bring this important product to market."

With over 20 years of experience within the consumer market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current consumer roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Consumer
Return to news